C-peptide (C-Peptide) antibody and antigen (Recombinant protein)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-h-C-Peptide-Ag01	Recombinant human AHSG/C-Peptide/FETUA/PRO2743 Protein	3090
GMP-h-C-Peptide-Ab01	Anti-human AHSG/C-Peptide/FETUA/PRO2743 mouse monoclonal antibody (mAb)	1953
GMP-h-C-Peptide-Ab02	Anti-human AHSG/C-Peptide/FETUA/PRO2743 mouse monoclonal antibody (mAb)	1953
GMP-h-C-Peptide-Ab03	Anti-human AHSG/C-Peptide/FETUA/PRO2743 human monoclonal antibody (mAb)	1953
GMP-h-C-Peptide-Ab04	Anti-human AHSG/C-Peptide/FETUA/PRO2743 human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-h-C-Peptide-Ag01
Product Name	Recombinant human AHSG/C-Peptide/FETUA/PRO2743 Protein
Target/Biomarker	C-peptide (C-Peptide)
Alias of Target/Biomarker	A2HS, AHS, APMR1, FETUA, HSGA
Expression platform	mammalian
Isotypes	Recombinant Antigen
Bioactivity validation	C-peptide (C-Peptide) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in C-Peptide level test of Diabetes diseases (type 1 diabetes mellitus) and related syndrome evaluation.
Tag	His
Products description	Recombinant human AHSG/C-Peptide/FETUA/PRO2743 Protein was expressed in mammalian expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-C-Peptide-Ab01, GMP-h-C-Peptide-Ab02
Product Name	Anti-human AHSG/C-Peptide/FETUA/PRO2743 mouse monoclonal antibody (mAb)
Target/Biomarker	C-peptide (C-Peptide)
Alias of Target/Biomarker	A2HS, AHS, APMR1, FETUA, HSGA
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	C-peptide (C-Peptide) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in C-Peptide level test of Diabetes diseases (type 1 diabetes mellitus) and related syndrome evaluation.
Tag	mFc
Products description	Anti-human AHSG/C-Peptide/FETUA/PRO2743 mouse monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-h-C-Peptide-Ab03, GMP-h-C-Peptide-Ab04
Product Name	Anti-human AHSG/C-Peptide/FETUA/PRO2743 human monoclonal antibody (mAb)
Target/Biomarker	C-peptide (C-Peptide)
Alias of Target/Biomarker	A2HS, AHS, APMR1, FETUA, HSGA
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	C-peptide (C-Peptide) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in C-Peptide level test of Diabetes diseases (type 1 diabetes mellitus) and related syndrome evaluation.
Tag	hFc
Products description	Anti-human AHSG/C-Peptide/FETUA/PRO2743 human monoclonal antibody (mAb) was expressed in CHO expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

C-peptide is a widely used measure of pancreatic beta cell function. It is produced in equimolar amounts to endogenous insulin but is excreted at a more constant rate over a longer time. Methods of estimation include urinary and unstimulated and stimulated serum sampling. Modern assays detect levels of c-peptide which can be used to guide diabetes diagnosis and management. C-peptide is a useful and widely used method of assessing pancreatic beta cell function [1, 2]. After cleavage of proinsulin, insulin and the 31-amino-acid peptide c-peptide are produced in equal amounts [3, 4]. So why is c-peptide testing preferable to insulin as a guide to beta cell function? The degradation rate of c-peptide in the body is slower than that of insulin (half-life of 20–30 min, compared with the half-life of insulin of just 3–5 min), which affords a more stable test window of fluctuating beta cell response. In healthy individuals the plasma concentration of c-peptide in the fasting state is 0.3–0.6 nmol/l, with a postprandial increase to 1–3 nmol/l [4]. Half of all insulin secreted by the pancreas is metabolized in the liver by first-pass metabolism, whereas c-peptide has negligible hepatic clearance. C-peptide is cleared in the peripheral circulation at a constant rate, whereas insulin is cleared variably making direct measurement less consistent. In insulin-treated patients with diabetes, measurement of c-peptide also avoids the pitfall of cross-reaction of assay between exogenous and endogenous insulin. C-peptide is a cornerstone of the assessment of non-diabetes-associated hypoglycemia and the diagnosis of conditions such as insulinoma and factitious hypoglycemia but this area is beyond the scope of this article. Increasing evidence suggests that c-peptide may also be useful in predicting future levels of glycemic control, response to hypoglycemic agents, and risk of future diabetes complications. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446389/

About GDU